Imaging and therapy agent developer Cytogen has named Dr. Nicholas Borys as vice president of medical affairs. Borys comes to Princeton, NJ-based Cytogen from Anthra Pharmaceuticals, where he served as vice president and medical director, focusing on oncology therapeutics.
He has also worked at Amersham Healthcare, where he directed clinical research and development for imaging agents and therapeutic pharmaceuticals. At Amersham, Borys directed clinical trials that for three products led to successful new drug applications (NDAs) to the Food and Drug Administration, according to Cytogen.
Borys will initially focus on supporting Cytogen's new direct sales effort for its ProstaScint and OncoScint cancer imaging agents. ProstaScint is targeted at prostate cancer, while OncoScint is aimed at colorectal and ovarian cancers.
By mid-year, Cytogen plans to file for regulatory approval in Europe for ProstaScint. The vendor has also noticed growing market interest in using OncoScint in imaging recurrent ovarian cancer, and will continue to emphasize the agent's potential value for that application, according to Borys.
By AuntMinnie.com staff writersFebruary 11, 2000
Copyright © 2000 AuntMinnie.com
